GeoVax Labs News

8-K: GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14 05:18

8-K: The Company Re-Convened a Special Meeting of Stockholders

Oct 17 04:33

8-K: GeoVax Labs, Inc. Increased the Maximum Aggregate Offering Price of the Shares Issuable

Oct 16 04:50

8-K: The Company Re-Convened a Special Meeting of Stockholders (The "special Meeting”) on October 1, 2024

Oct 2 05:21

8-K: Entry into an underwriting agreement

Sep 26 05:25

8-K: The Company Convened a Special Meeting of Stockholders on September 17, 2024

Sep 18 04:05

S-1: General form for registration of securities under the Securities Act of 1933

Sep 7 04:10

S-1: General form for registration of securities under the Securities Act of 1933

Sep 7 04:05

8-K: GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 31 04:18

8-K: Placement Agency Agreement

Aug 22 04:21

8-K: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8 04:10

S-1: General form for registration of securities under the Securities Act of 1933

Aug 7 05:14

DEF 14A: Definitive information statements

Aug 2 04:18

PRE 14A: Preliminary proxy statements relating to merger or acquisition

Jul 23 04:23

8-K: GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market

Jul 13 04:08

8-K: Current report

Jun 22 04:07

8-K: GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1

Jun 19 01:18

S-1: General form for registration of securities under the Securities Act of 1933

Jun 8 04:09

8-K: Current report

May 25 04:51

GeoVax Labs | 8-K: Poll Results of GeoVax Labs Meeting

May 24 04:14